Advertisement
Brief report| Volume 40, ISSUE 6, P550-552, September 15, 1996

Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic

DOI:https://doi.org/10.1016/0006-3223(96)00163-1
Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic
Previous ArticleIntranasal oxytocin in obsessive-compulsive disorder
Next ArticleUrinary epinephrine excretion during intelligence testing in attention-deficit hyperactivity disorder and normal boys
      This paper is only available as a PDF. To read, Please Download here.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Bammert Adams J
        • Pyke RE
        • Costa J
        • et al.
        A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.
        J Clin Psychopharmacol. 1995; 15: 428-434
        • Bradwejn J
        • Koszycki D
        • Shriqui C
        Enhanced sensitivity to cholecystokinin-tetrapeptide in panic disorder: Clinical and behavioral findings.
        Arch Gen Psychiatry. 1991; 48: 603-610
        • Bradwejn J
        • Koszycki D
        • Couetoux du Tetre A
        • et al.
        The panicogenic effects of cholecystokinin tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
        Arch Gen Psychiatry. 1994; 51: 486-493
        • Bradwejn J
        • Paradis M
        • Koszycki D
        • Reece P
        • Sedman A
        The effects of CI-988 on CCK-4-panic in healthy volunteers.
        in: Presented at the annual meeting of the ACNP. 1994
        • Cowley D
        • Arana G
        The diagnostic utility of lactate sensitivity in panic disorder.
        Arch Gen Psychiatry. 1990; 47: 277-284
        • Powell KR
        • Barrett JE
        Evaluation of the effects of PD 134308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys.
        Neuropeptides. 1991; 19 (suppl): 75-78
        • Singh L
        • Field M
        • Hughes J
        • et al.
        The behavioural properties of CI-988, a selective cholecystokinin B receptor antagonist.
        Br J Pharmacol. 1991; 104: 239-245
        • Singh L
        • Lewis A
        • Field M
        • Hughes J
        • Woodruff G
        Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
        in: Proc Natl Acad Sci USA. 88. 1991: 1130-1133
        • Van der Molen GM
        • van den Hout MA
        • Vroeman J
        • Lousberg H
        • Griez E
        Cognitive factors in lactate-induced anxiety.
        Behav Res Ther. 1986; 24: 677-680
        • Westenberg H
        • van Megen HGM
        • den Boer JA
        Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic in panic disorder (PD) patients.
        Psychopharmacol Bull. 1994; 30: 644

      Article info

      Publication history

      Received in revised form: March 6, 1996
      Received: November 24, 1995

      Footnotes

      This study was funded by a grant from Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company.

      Identification

      DOI: https://doi.org/10.1016/0006-3223(96)00163-1

      Copyright

      © 1996 Society of Biological Psychiatry. Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX